News Center

Highlights

  • 12

    31
    2019,Tue

    Lumosa Received LT5001 IND Approval from TFDA for the Treatment of Uremic Pruritus

    Phase Ib/II Trial will Commence Soon in Taiwan

  • 12

    02
    2019,Mon

    Lumosa Licensed LT1001 to Jemincare in China

  • 11

    26
    2019,Tue

    Lumosa Announces FDA Acceptance of IND Application for LT1001, an Extended-Release Analgesic Injection Lumosa to Initiate the Bridging Study in the US

more news

Press Release

  • 2019 1231

    CATEGORY Press Release

    Lumosa Received LT5001 IND Approval from TFDA for the Treatment of Uremic Pruritus

    Phase Ib/II Trial will Commence Soon in Taiwan

    Read More
  • 2019 1202

    CATEGORY Press Release

    Lumosa Licensed LT1001 to Jemincare in China

    Read More
  • 2019 1126

    CATEGORY Press Release

    Lumosa Announces FDA Acceptance of IND Application for LT1001, an Extended-Release Analgesic Injection Lumosa to Initiate the Bridging Study in the US

    Read More
  • 2019 1106

    CATEGORY Press Release

    LT3001 China Region Out-Licensed to SHP

    Read More
  • 2019 0731

    CATEGORY Press Release

    Naldebain to Enter Switzerland

    Read More
+Close